Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 2001, p. 23-29, Vol. 45, No. 1
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.1.23-29.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Pharmacodynamics of Telithromycin In Vitro against
Respiratory Tract Pathogens
Inga
Odenholt,*
Elisabeth
Löwdin, and
Otto
Cars
Antibiotic Research Unit, Department of
Infectious Diseases and Clinical Microbiology, University Hospital,
Uppsala, Sweden
Received 28 February 2000/Returned for modification 14 May
2000/Accepted 3 September 2000
 |
ABSTRACT |
Telithromycin (HMR 3647) is a new ketolide that belongs to a new
class of semisynthetic 14-membered-ring macrolides which have expanded
activity against multidrug-resistant gram-positive bacteria. The aim of
the present study was to investigate different basic pharmacodynamic
properties of this new compound. The following studies of telithromycin
were performed: (i) studies of the rate and extent of killing of
respiratory tract pathogens with different susceptibilities to
erythromycin and penicillin exposed to a fixed concentration that
corresponds to a dose of 800 mg in humans, (ii) studies of the rate and
extent of killing of telithromycin at five different concentrations,
(iii) studies of the rate and extent of killing of the same pathogens
at three different inocula, (iv) studies of the postantibiotic effect
and the postantibiotic sub-MIC effect of telithromycin, and (v)
determination of the rate and extent of killing of telithromycin in an
in vitro kinetic model. In conclusion, telithromycin exerted an
extremely fast killing of all strains of Streptococcus
pneumoniae both with static concentrations and in the in vitro
kinetic model. A slower killing of the strains of Streptococcus
pyogenes was noted, with regrowth in the kinetic model of a
macrolide-lincosamide-streptogramin B-inducible strain. The strains of
Haemophilus influenzae were not killed at all at a
concentration of 0.6 mg/liter due to high MICs. A time-dependent
killing was seen for all strains. No inoculum effect was seen for the
strains of S. pneumoniae, with a 99.9% reduction in the
numbers of CFU for all inocula at both 8 h and 24 h. The
killing of the strains of S. pyogenes was reduced by 1 log10 CFU at 8 h and 2 to 3 log10 CFU at
24 h when the two lower inocula were used but not at all at 8 and
24 h when the highest inoculum was used. For both of the H. influenzae strains there was an inoculum effect, with 1 to 2 log10 CFU less killing for the inoculum of 108
CFU/ml in comparison to that for the inoculum of 106
CFU/ml. Overall, telithromycin exhibited long postantibiotic effects
and postantibiotic sub-MIC effects for all strains investigated.
 |
INTRODUCTION |
Ketolides are semisynthetic
14-membered-ring macrolides. The ketolides, in contrast to the older
macrolides, lack the neutral sugar L-cladinose at position
3 and possess a 3-keto group instead of a 3-hydroxyl group at position
3. This has led to improved acid stability as well as a higher
intrinsic activity against gram-positive cocci compared to that of
erythromycin (6). The ketolides have the same
antibacterial spectra as other macrolides. However, they are also
active against Streptococcus pneumoniae and
Streptococcus pyogenes, which are resistant to erythromycin A (inducible and constitutive resistance), and against
Staphylococcus aureus strains with an inducible resistance
mechanism toward erythromycin A but not S. aureus strains
with a constitutive resistance mechanism (1, 2, 5, 12, 14,
18-20). In humans telithromycin (HMR 3647) has pharmacokinetic
properties similar to those of erythromycin. With a dose of 800 mg of
telithromycin, a maximum concentration in serum
(Cmax) of 2 mg/liter is obtained in human serum,
and with a protein binding of approximately 70%, a free unbound
concentration of drug of 0.6 mg/liter is reached. Telithromycin, however, exhibits a much longer half-life (12 h) compared to that (2 h)
of erythromycin (Hoechst, Marion & Roussel, Romanville, France, data on file).
In the past decade pharmacodynamic parameters have become increasingly
important for determination of the optimal antibiotic dosing schedules
(10-12, 17, 18; J. Dubois and C. St.-Pierre, Abstr.
39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1242, p.
257, 1999). The aim of the present study was to investigate the basic
pharmacodynamics of telithromycin such as the rate and extent of
killing at a concentration corresponding to the unbound 2-h level in
serum following administration of a dose of 800 mg (0.6 mg/liter) to
humans, the level of killing at different concentrations and at
different inocula, the postantibiotic effects (PAEs), the postantibiotic sub-MIC effects (PA SMEs), and the extent of killing in
an in vitro kinetic model.
(This material was presented in part at the 39th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., 26 to 29 September 1999.)
 |
MATERIALS AND METHODS |
Antibiotic.
Telithromycin was provided by Hoechst, Marion & Roussel. The antibiotic was obtained as a reference powder with known
potency. The substance was dissolved in 10 ml of distilled water and 2 µl of glacial acetic acid and thereafter was diluted in broth. The
solutions were made on the same day that the experiments were performed.
Bacterial strains and media.
The strains used in the study
included S. pneumoniae ATCC 6306 (penicillin susceptible),
S. pneumoniae 950607-126 (penicillin intermediate), S. pneumoniae 2151 (penicillin resistant), S. pyogenes group A, NCTC (National Collection of Type Cultures) P1800
(erythromycin sensitive), S. pyogenes group A 197 (erythromycin resistant macrolide-lincosamide-streptogramin B
[MLSB] inducible), S. pyogenes group A 138 (erythromycin resistant by an efflux mechanism), Haemophilus
influenzae CCUG (Culture Collection University of Gothenburg)
23969 (
-lactamase producing), and H. influenzae NCTC 8468 (non-
-lactamase producing). The clinical strains of S. pneumoniae were obtained from the Clinical Microbiological Laboratory, University Hospital, Uppsala, Sweden. The strains of
S. pyogenes came from and were also characterized at the
Department of Bacteriology, Swedish Institute for Infectious Disease
Control, Solna, Sweden. The gram-positive strains were grown in
Todd-Hewitt broth for 6 h at 37°C in 5% CO2 in air,
resulting in approximately 5 × 108 CFU/ml. H. influenzae was grown in Mueller-Hinton broth (Difco Laboratories,
Detroit, Mich.) supplemented with 50 mg of hemin per liter and 1%
IsoVitaleX for 6 h at 37°C, yielding an initial inoculum of
approximately 109 CFU/ml.
Determination of MICs.
The MICs of telithromycin for the
strains investigated were determined in triplicate on different
occasions by the macrodilution technique according to the guidelines of
the National Committee for Clinical Laboratory Standards
(15). Twofold serial dilutions of the antibiotics were
added to broth, that mixture was inoculated with a final inoculum of
approximately 105 CFU of the test strain per ml, and the
entire mixture was incubated at 37°C for 24 h. The MIC was
defined as the lowest concentration of the antibiotic that allowed no
visible growth. The MICs of benzylpenicillin and erythromycin for the
same strains were performed by E-tests (Biodisk, Solna, Sweden).
Determination of telithromycin concentrations.
The
concentrations of telithromycin during the vitro kinetic experiments
were determined by a microbiological agar diffusion method with
Micrococcus luteus ATCC 9341 as the test organism. A
standardized inoculum of the bacterial suspension was mixed with
tryptone-glucose agar that had been adjusted to pH 7.4, and the mixture
was poured into plates. After the plates were dried, 0.03-ml volumes of
all samples and standards diluted in Todd-Hewitt broth were placed in
agar wells, and three parallel determinations were made
(8).
(i) Determination of killing by telithromycin at a constant
concentration of 0.6 mg/liter.
The free unbound concentration
corresponding to a telithromycin dose of 800 mg was used in these
experiments. Tubes containing medium to which antibiotic had been added
were inoculated with a suspension of the test strain, giving a final
bacterial count of approximately 5 × 105 CFU/ml, and
the tubes were incubated at 37°C. One sample was withdrawn at each of
various times (0, 1, 2, 3, 6, 9, 12, and 24 h), and if necessary,
the sample was diluted in phosphate-buffered saline. At least three
dilutions of each sample (10
1, 10
2,
10
3) were spread onto blood agar plates (Colombia agar
base with 5% horse blood), the plates were incubated at 37°C, and
the colonies were counted after 24 h. The sensitivity of the
method was 1 × 101 to 5 × 101
CFU/ml. Telithromycin was tested against S. pneumoniae ATCC
6306, 1020, 2151, S. pyogenes group A, NTCC P1800, 138, and
197, and H. influenzae NTCC 8468 and CCUG 23969. The
experiments were performed in duplicate for each antibiotic-bacterium combination.
(ii) Determination of killing by telithromycin at different
concentrations.
In the second study, different concentrations of
telithromycin were used. Tubes containing 4 ml of broth to which
antibiotic had been added at concentrations of 2, 4, 8, 16, and 32 times the MIC were inoculated with a suspension of the test strain, giving a final bacterial count of approximately 5 × 105 CFU/ml. The tubes were thereafter incubated at 37°C
and samples were withdrawn at 0, 1, 2, 3, 6, 9, 12, and 24 h and
seeded as described above. The strains tested were S. pneumoniae ATCC 6306, S. pneumoniae 2151, S. pyogenes NTCC P1800, S. pyogenes 138, S. pyogenes 197, H. influenzae CCUG 23969, and H. influenzae NTCC 8468. The experiments were performed in duplicate
for all strains.
(iii) Determination of killing by telithromycin with different
inocula.
In the third set of experiments, S. pneumoniae
ATCC 6306, S. pneumoniae 2151, S. pyogenes 138, S. pyogenes 197, H. influenzae CCUG 23969, and
H. influenzae NTCC 8468 at three different inocula (approximately 104, 106, and 108
CFU/ml) were exposed to telithromycin at a concentration of four times
the MIC for each strain. Killing curve studies were performed as
described above. The experiments were performed in duplicate for all strains.
(iv) Determination of PAEs and PA SMEs.
The PAEs and the PA
SMEs of telithromycin were investigated against S. pyogenes
group A 197, S. pyogenes group A 138, H. influenzae CCUG 23969, and H. influenzae NTCC 8468. After incubation for 6 h, the test strains in the exponential
growth phase were diluted 10
1 to obtain a starting
inoculum of 5 × 107 to 1 × 108
CFU/ml. The strains were then exposed to 10 times the MIC of the
antibiotic for 2 h at 37°C. To eliminate the antibiotic, the cultures were washed three times, centrifuged each time at
1,400 × g for 5 min, and diluted 10
2 in
fresh medium. Depending on the killing, some of the cultures were
thereafter further diluted to obtain an inoculum of approximately 105 CFU/ml. The unexposed control strains were washed
similarly and diluted 10
3 to 10
4 in order
to obtain an inoculum as close to that of the exposed strains as
possible. The cultures with bacteria in the postantibiotic phase and
the controls were thereafter divided into four different tubes. In
order to determine the PAE, one tube of each culture was reincubated at
37°C for another 22 h. Samples were withdrawn at 0 and 2 h
(before and after dilution, respectively) and at 3, 4, 5, 6, 8, 12, and
24 h, and if necessary, they were diluted in phosphate-buffered
saline. In some experiments, samples were also taken at 14 h.
Three dilutions of each sample were seeded onto blood agar plates and
the colonies were counted for determination of the number of CFU.
The PAE was defined according to the following formula
(9): PAE = T
C, where T
is the time required for the viable counts of the antibiotic-exposed
cultures to increase by 1 log10 above the counts observed
immediately after washing, and C is the corresponding time
for the controls.
After washing and dilution of the cultures, the remaining three tubes
of the control cultures and the cultures in the postantibiotic
phase
were exposed to telithromycin at concentrations 0.1, 0.2,
and 0.3 time
the MIC, and the cultures were reincubated at 37°C
for another
22 h. Samples were withdrawn, and the counts of the
viable
bacteria were determined as described
above.
The PA SME was defined according to the following formula
(
16): PA SME =
TPA
C, where
TPA is the time required for
the
viable counts of the previously antibiotic-exposed cultures, which
thereafter had been exposed to different sub-MICs of telithromycin,
to
increase by 1 log
10 above the counts observed immediately
after
washing, and
C is the corresponding time for the
unexposed control.
All antibiotic-bacterium combinations were
investigated in
duplicate.
(v) Determination of killing by telithromycin in an in vitro
kinetic model.
A recently described model was used to determine
the killing by telithromycin in an in vitro kinetic model
(13). It consists of a spinner flask (volume, 100 ml;
Bellco spinner flask; Bellco Glass Inc., Vineland, N.J.) with a
0.45-mm-pore-size filter membrane and a prefilter between the upper and
the bottom parts. A magnetic stirrer ensures homogeneous mixing of the
culture and prevents membrane pore blockage. A silicon membrane is
inserted in one of the side arms of the culture vessel to enable
repeated sampling. The other arm is connected by a thin plastic tubing
to a vessel containing fresh medium. The medium is removed from the
culture flask at a constant rate with a pump and passes through the
filter. Fresh sterile medium is sucked into the flask at the same rate by the negative pressure built up inside the culture vessel. The antibiotic was added to the vessel and was eliminated at a constant rate according to first-order kinetics, such that C = C0 · e
kt, where
C0 is the initial antibiotic level, C
is the antibiotic level at time t, k is the rate
of elimination, and t is the time that has elapsed since the
addition of antibiotic. During the experiments the apparatus was placed
in a room kept thermostatic at 37°C. The culture vessel was
sterilized by autoclaving between every experiment. The medium used was
Todd-Hewitt broth saturated with CO2. Telithromycin was
added to the medium once at time zero at a concentration of 0.6 mg/liter and tested against the strains of S. pyogenes with
a simulated half-life of 12 h. Due to the very fast killing of the
strains of S. pneumoniae seen in the previous experiments,
an initial concentration of two times the MIC was used instead. One
sample was withdrawn at various times (0, 1, 2, 3, 6, 8, 12, and
24 h) and was seeded as described above. The bacteria investigated
were S. pneumoniae ATCC 6306, S. pneumoniae 2151, S. pyogenes 138, and S. pyogenes 197. The
experiments were performed in triplicate for each bacterial strain.
 |
RESULTS |
MICs.
The MICs for the various strains are shown in Table
1. The MICs of telithromycin were within
the range found by other investigators (1, 2, 5, 12, 14,
18-20). The highest MICs of telithromycin were, as reported for
other macrolides, noted against H. influenzae (2, 4,
19).
Antibiotic concentrations.
The concentrations of telithromycin
in the in vitro kinetic model were 0.62 ± 0.03, 0.45 ± 0.04, 0.31 ± 0.02, and 0.16 ± 0.01 mg/liter (mean ± standard deviation) at 0, 6, 14, and 24 h, respectively. The
correlation coefficients for the standard curves were
0.98. The limit
of detection was 0.06 mg/liter. The half-life was calculated to be
12.5 h.
(i) Killing by telithromycin at a constant concentration of 0.6 mg/liter.
An extremely fast killing (>3 log10 CFU/ml
after 1 h) of all the strains of S. pneumoniae was
noted, irrespective of whether the strain was penicillin susceptible or
not (Fig. 1a; Table
2). A slower killing of the strains of
S. pyogenes (<2 log10 CFU/ml after 12 h)
was seen, but there was no difference in the rate of killing between
the strains (Fig. 1b; Table 2). As anticipated, no killing of H. influenzae CCUG 23969 was noted at all due to the high MIC for
this strain. An initial killing of 1 log10 CFU of H. influenzae NTCC 8468 per ml was noted, but regrowth was seen at
12 h (Fig. 1c; Table 2).



View larger version (50K):
[in this window]
[in a new window]
|
FIG. 1.
(a) Killing curves for telithromycin at a concentration
of 0.6 mg/liter against S. pneumoniae ATCC 6306 ( ),
S. pneumoniae 1020 ( ), S. pneumoniae 2151 ( ). Control strains were S. pneumoniae ATCC 6306 ( ),
S. pneumoniae 1020 ( ), and S. pneumoniae 2151 ( ). (b) S. pyogenes NTCC P1800 ( ), S. pyogenes 197 ( ), S. pyogenes 138 ( ). (c) H. influenzae NTCC 8468 ( ), and H. influenzae CCUG
23969 ( ). Controls strains were H. influenzae NTCC 8468 ( ) and H. influenzae CCUG 23969 ( ).
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Killing of gram-positive and gram-negative strains by
telithromycin at a constant concentration of 0.6 mg/liter
|
|
(ii) Killing by telithromycin at different concentrations.
A
non-concentration-dependent killing of all strains investigated was
seen. Also, it was noted that telithromycin exerted a slower
bactericidal effect against S. pyogenes in comparison to its
effect against S. pneumoniae. A slow bactericidal effect was
also seen against H. influenzae, and as noted in the first set of experiments, telithromycin at all concentrations exerted a
significantly slower bactericidal effect against H. influenzae CCUG 23969 in comparison to that against H. influenzae NTCC 8468 (Table 3).
(iii) Killing by telithromycin with different inocula.
Even at
the highest inoculum, there was a >3 log10 CFU/ml killing
by telithromycin of the strains of S. pneumoniae after 8 and
24 h. The killing of the strains of S. pyogenes was
reduced by approximately 1 log10 CFU at 8 h and 2 to 3 log10 CFU at 24 h when the two lower inocula were used
but not at all at 8 and 24 h when the highest inoculum was used
(Fig. 2). For both of the H. influenzae strains there was an inoculum effect, with 1 to 2 log10 CFU less killing for the inoculum of 108
CFU/ml in comparison to that for the inoculum of 106 CFU/ml
(Table 4).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
Killing curves for telithromycin against S. pneumoniae 2151 at starting inocula of approximately
104 CFU/ml ( ), 106 CFU/ml ( ), and
108 CFU/ml ( ) and against S. pyogenes 197 at
starting inocula of approximately 104 CFU/ml ( ),
106 CFU/ml ( ), and 108 CFU/ml ( ).
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Killing of gram-positive and gram-negative strains at
different inocula by telithromycin at four times the MIC
|
|
(iv) PAEs and PA SMEs of telithromycin.
Telithromycin
exhibited a PAE of over 6 h against all strains investigated; the
longest PAE (12.4 h) was seen against H. influenzae NTCC
8468. The PA SMEs at 0.3 time the MIC were between 14 and over 20 h (Table 5).
(v) Killing in in vitro kinetic model.
The time above the MIC
(T > MIC) and the area under the concentration-time
curve (AUC)/MIC values for the different strains are presented in Table
6. The bactericidal effect of
telithromycin against the strains of S. pneumoniae in the
kinetic model was as pronounced as that seen with static
concentrations, even though the bacteria were exposed to the drug at
concentrations only two times the MIC. A 99.9% reduction in the
numbers of CFU was reached after 1 and 2 h for the
penicillin-resistant and -sensitive strains, respectively. A
bactericidal effect was not achieved for any of the S. pyogenes strains, and regrowth was seen with the
MLSB-inducible strain of S. pyogenes after
24 h, even though a high AUC/MIC was reached and the
T > MIC was over 100% for this strain (Fig.
3; Table 6).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
Killing curves for telithromycin in the in vitro kinetic
model. The half-life was 12 h. , S. pneumoniae ATCC
6306 (Cmax = 0.008 mg/liter); , S. pneumoniae 2151 (Cmax = 0.032 mg/liter); , S. pyogenes 197 (Cmax = 0.6 mg/liter); , S. pyogenes 138 (Cmax = 0.6 mg/liter).
Controls were S. pneumoniae ATCC 6306 ( ), S. pneumoniae R-2151 ( ), S. pyogenes 197 (×), and
S. pyogenes 138 ( ).
|
|
 |
DISCUSSION |
In order to investigate the basic pharmacodynamics of
telithromycin, we chose to study the time-killing curves obtained with a fixed concentration, different concentrations, and fluctuating concentrations of telithromycin in an in vitro kinetic model. Furthermore, the inoculum effect, the PAE, and the PA SME of
telithromycin were investigated. Low MICs of telithromycin were found
in this study for all the strains of S. pneumoniae, whether
or not they were penicillin resistant, and also for the
erythromycin-sensitive strain of S. pyogenes and the
MLSB-inducible strain. Higher MICs were found for the
strain of S. pyogenes resistant due to an efflux mechanism
and for the strains of H. influenzae. The high MICs for the
latter strains are similar to those of older macrolides and are
consistent with the findings of other investigators (2, 5,
19). In the time-killing curve studies, it was found that telithromycin at a concentration that corresponded to the unbound 2-h
level in serum following administration of a dose of 800 mg in humans
exerted an extremely fast bactericidal activity against the strains of
S. pneumoniae, irrespective of whether the strain was
penicillin resistant. Similar findings were described by Pankuch et al.
(18), who also found a uniform bactericidal killing of telithromycin at concentrations
0.25 mg/liter after 24 h against different strains of S. pneumoniae, and also by Boswell et
al. (4), who showed that telithromycin at 10 times the MIC
was bactericidal at 4 to 6 h against S. pneumoniae
strains. This is in contrast to the older macrolides, which have mostly
a bacteriostatic action or which have a very slow bactericidal effect
against gram-positive bacteria (7). In our study, as in
the study of Boswell et al. (4), the strains of S. pyogenes were killed more slowly in comparison to the rate of
killing of S. pneumoniae strains. A 99.9% reduction in the
number of CFU was achieved first at 24 h for the
erythromycin-sensitive strain of S. pyogenes and the MLSB-inducible strain. For the strain of S. pyogenes with the efflux mechanism of resistance, a
2.5-log10 reduction was noted after 24 h. Our findings
with a fixed concentration for these strains were also confirmed in the
in vitro kinetic model, in which regrowth was also noticed for the
MLSB-producing strain, even though a high AUC/MIC was
reached and the T > MIC was 100% over 24 h. No
bactericidal activity was noted for the strains of H. influenzae at the simulated concentration in serum of 0.6 mg/liter. As reported for older macrolides and azalides, no enhancement of the antibacterial effect was noted with higher concentrations of
telithromycin (7). In the first set of experiments, even at a concentration of two times the MIC, very fast killing of the
strains of S. pneumoniae compared with the rate of killing of S. pyogenes and H. influenzae strains was
seen. However, a 99.9% reduction in the numbers of CFU was achieved at
12 and 24 h with a concentration of four times the MIC for
H. influenzae NTCC 8468 and CCUG 23969, respectively, but
this concentration (8 to 16 mg/liter) is not achievable in human serum
but could be relevant for infections in the lungs, in which
concentrations in alveolar macrophages and epithelial lining fluid of
65 and 5.4 mg/liter have been reached (Hoechst, Marion & Roussel, data on file).
There have been reports that the antibacterial effects of macrolides
against staphylococci may be affected by the inoculum size
(7). However, in the case of dirithromycin, Biedenbach et
al. (3) found no inoculum effect for S. pneumoniae or H. influenzae. Boswell et al.
(4) noted an inoculum effect when strains of S. pneumoniae and H. influenzae were exposed to
telithromycin at a concentration of 2 times the MIC, but the effect was
less pronounced when the bacteria were exposed to a concentration of 10 times the MIC. When S. pyogenes strains at different inocula were exposed to concentrations of 2 and 10 times the MIC, no inoculum effect was found (4). In another study by the same
investigators (5), there was no change in the MIC of
telithromycin for S. aureus, Enterococcus
faecalis, Moraxella catarrhalis, or Nesseria meningitidis when the inoculum was raised from 104 to
106 CFU/ml (5). In the present study, >99.9%
killing was achieved for both strains of S. pneumoniae at
all inocula at both 8 and 24 h. As seen earlier, the strains of
S. pyogenes were killed much more slowly, and at the highest
inoculum the strains were not killed at all at either time point. For
both of the H. influenzae strains, there was an inoculum
effect, with 1 to 2 log10 CFU less killing for the inoculum
of 108 CFU/ml in comparison to that for the inoculum of
106 CFU/ml. Persistent suppression of growth after
intermittent drug exposure, the so-called PAE, also influences the time
course of antibacterial activity (9, 10). Macrolides,
azalides, and ketolides in general have long PAEs compared, for
example, with those of
-lactam antibiotics (9, 10, 17).
In an earlier study of the pharmacodynamics of clarithromycin,
roxithromycin, and azithromycin, we found PAEs of 4 to 5 h, for
S. pyogenes, 3 to 9 h for S. pneumoniae, and
5 to 8 h for a strain of H. influenzae (17). Somewhat longer PAEs were found in this study of
telithromycin: PAEs ranged from 7.4 to 9.8 h for S. pyogenes and from 6.7 to 12.4 for the H. influenzae
strains. Dubois and St-Pierre (39th ICAAC) reported similar values;
they found PAEs of 6 to 9 h for S. pyogenes and 4 to
5 h for H. influenzae. Boswell et al. (4) found PAEs for the same species of 3.7 to 5.8 and 2.2 to 6.2 h, respectively. Since drug levels in vivo do not immediately fall to
undetectable values, as in the standard methodology for measurement of
the PAE in vitro, PA SMEs were also studied. Results very similar to
those found for clarithromycin, roxithromycin, and azithromycin were
found (17). The durations of the PAEs were prolonged
approximately 30% by exposure in the postantibiotic phase to a
concentration of 0.1 time the MIC and approximately 50% by exposure to
a concentration of 0.3 time the MIC. Somewhat lower figures were found
for S. pyogenes 197 (13 and 40%, respectively).
In conclusion, telithromycin exerted an extremely fast killing of all
strains of S. pneumoniae both with static concentrations and
in the in vitro kinetic model. Slower killing of all the strains of
S. pyogenes was noted, with regrowth of the
MLSB-inducible strain in the kinetic model detected. As
expected, the strains of H. influenzae were not killed at
all at a concentration of 0.6 mg/liter since this concentration was
below the MICs for the strains. Time-dependent killing was seen for all
strains. In these experiments it was also noted that telithromycin
exerted a slower bactericidal effect against S. pyogenes in
comparison to the rate of the effect against S. pneumoniae.
No inoculum effect was seen for the strains of S. pneumoniae, with a 99.9% reduction in the numbers of CFU at all
inocula at 8 and 24 h. As seen earlier, the strains of S. pyogenes were killed more slowly, and at the highest inoculum the
S. pyogenes strains were not killed at all. For both of the
H. influenzae strains tested, there was an inoculum effect,
with 1 to 2 log10 CFU less killing for the inoculum of 108 CFU/ml in comparison to that for the inoculum of
106 CFU/ml. Telithromycin exerted long PAEs and PA SMEs for
all strains investigated.
 |
ACKNOWLEDGMENTS |
This work was supported by a grant from Hoechst, Marion & Roussel, Romanville Cedex, France.
We thank Anita Perols, Ingegerd Gustavsson, and Eva Tanou for skillful assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Infectious Diseases, University Hospital, MAS, S-20502 Malmö,
Sweden. Phone: (46)-40-331806. Fax: (46)-40-336279. E-mail:
inga.odenholt{at}inf.mas.lu.se.
 |
REFERENCES |
| 1.
|
Barry, A. L.,
P. C. Fuchs, and S. D. Brown.
1998.
Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinopristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).
Antimicrob. Agents Chemother.
42:945-946[Abstract/Free Full Text].
|
| 2.
|
Barry, A. L.,
P. C. Fuchs, and S. D. Brown.
1998.
In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae.
Antimicrob. Agents Chemother.
42:2138-2140[Abstract/Free Full Text].
|
| 3.
|
Biedenbach, D. J.,
R. N. Jones,
M. T. Lewis,
M. A. Croco, and M. S. Barrett.
1999.
Comparative in vitro evaluation of dirithromycin tested against recent isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
Diagn. Microbiol. Infect. Dis.
33:275-282[CrossRef][Medline].
|
| 4.
|
Boswell, F. J.,
J. M. Andrew, and R. Wise.
1998.
Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect.
J. Antimicrob. Chemother.
41:149-153[Abstract/Free Full Text].
|
| 5.
|
Boswell, F. J.,
J. M. Andrew,
J. P. Ashby,
C. Fogarty,
N. P. Brenwald, and R. Wise.
1998.
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.
J. Antimicrob. Chemother.
42:703-709[Abstract/Free Full Text].
|
| 6.
|
Bryskier, A.,
C. Agouridas, and J.-F. Chantot.
1997.
Ketolides: new semisynthetic 14-membered-ring macrolides, p. 39-50.
In
S. H. Zinner (ed.), Expanding indications for the new macrolides, azalides, and streptogramins. Marcel Dekker, Inc., New York, N.Y.
|
| 7.
|
Carbon, C.
1998.
Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens.
Clin. Infect. Dis.
27:28-32[Medline].
|
| 8.
|
Cars, O.,
C. Henning, and S. Holm.
1981.
Penetration of ampicillin and dicloxacillin into tissue cage fluid in rabbits: relation to serum and tissue protein binding.
Scand. J. Infect. Dis.
13:69-74[Medline].
|
| 9.
|
Craig, W. A., and S. Gudmundsson.
1996.
The postantibiotic effect, p. 296-329.
In
V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
|
| 10.
|
Craig, W. A.
1997.
Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins, p. 27-38.
In
S. H. Zinner (ed.), Expanding indications for the new macrolides, azalides, and streptogramins. Marcel Dekker, Inc., New York, N.Y.
|
| 11.
|
Craig, W. A.
1998.
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men.
Clin. Infect. Dis.
26:1-12[Medline].
|
| 12.
|
Hamilton-Miller, J. M., and S. Shah.
1998.
Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status.
J. Antimicrob. Chemother.
41:649-653[Abstract/Free Full Text].
|
| 13.
|
Löwdin, E.,
I. Odenholt, and O. Cars.
1996.
Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model.
Antimicrob. Agents Chemother.
40:2478-2482[Abstract].
|
| 14.
|
Malathum, K.,
T. M. Coque,
K. V. Singh, and B. E. Murrey.
1999.
In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.
Antimicrob. Agents Chemother.
43:930-936[Abstract/Free Full Text].
|
| 15.
|
National Committee for Clinical Laboratory Standards.
1992.
Methods for determining bactericidal activity of antimicrobial agents; tentative guideline M26-T.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 16.
|
Odenholt, I.,
E. Löwdin, and O. Cars.
1991.
Pharmacodynamic effects of subinhibitory concentrations of -lactam antibiotics in vitro.
Antimicrob. Agents Chemother.
35:1834-1839[Abstract/Free Full Text].
|
| 17.
|
Odenholt, I.,
E. Löwdin, and O. Cars.
1995.
Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.
Antimicrob. Agents Chemother.
39:221-226[Abstract].
|
| 18.
|
Pankuch, G. A.,
M. A. Visalli,
M. R. Jacobs, and P. C. Appelbaum.
1998.
Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.
Antimicrob. Agents Chemother.
42:624-630[Abstract/Free Full Text].
|
| 19.
|
Piper, K. E.,
M. S. Rouse,
J. M. Steckelberg,
W. R. Wilson, and R. Patel.
1999.
Ketolide treatment of Haemophilus influenzae experimental pneumonia.
Antimicrob. Agents Chemother.
43:708-710[Abstract/Free Full Text].
|
| 20.
|
Reinert, R. R.,
A. Bryskier, and R. Lütticken.
1998.
In-vitro activities of the new ketolide HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany.
Antimicrob. Agents Chemother.
42:1509-1511[Abstract/Free Full Text].
|
Antimicrobial Agents and Chemotherapy, January 2001, p. 23-29, Vol. 45, No. 1
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.1.23-29.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zeitlinger, M., Sauermann, R., Fille, M., Hausdorfer, J., Leitner, I., Muller, M.
(2008). Plasma protein binding of fluoroquinolones affects antimicrobial activity. J Antimicrob Chemother
61: 561-567
[Abstract]
[Full Text]
-
Zhanel, G. G., Johanson, C., Laing, N., Hisanaga, T., Wierzbowski, A., Hoban, D. J.
(2005). Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (mefE)-Producing Macrolide- Resistant Streptococcus pneumoniae for Which Telithromycin MICs Vary. Antimicrob. Agents Chemother.
49: 1943-1948
[Abstract]
[Full Text]
-
Kasbekar, N., Acharya, P. S.
(2005). Telithromycin: The first ketolide for the treatment of respiratory infections. Am J Health Syst Pharm
62: 905-916
[Abstract]
[Full Text]
-
Tessier, P. R., Mattoes, H. M., Dandekar, P. K., Nightingale, C. H., Nicolau, D. P.
(2005). Pharmacodynamic Profile of Telithromycin against Macrolide- and Fluoroquinolone-Resistant Streptococcus pneumoniae in a Neutropenic Mouse Thigh Model. Antimicrob. Agents Chemother.
49: 188-194
[Abstract]
[Full Text]
-
Zhanel, G. G., Johanson, C., Hisanaga, T., Mendoza, C., Laing, N., Noreddin, A., Wierzbowski, A., Hoban, D. J.
(2004). Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J Antimicrob Chemother
54: 1072-1077
[Abstract]
[Full Text]
-
Regoes, R. R., Wiuff, C., Zappala, R. M., Garner, K. N., Baquero, F., Levin, B. R.
(2004). Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens. Antimicrob. Agents Chemother.
48: 3670-3676
[Abstract]
[Full Text]
-
Novotny, G. W., Jakobsen, L., Andersen, N. M., Poehlsgaard, J., Douthwaite, S.
(2004). Ketolide Antimicrobial Activity Persists after Disruption of Interactions with Domain II of 23S rRNA. Antimicrob. Agents Chemother.
48: 3677-3683
[Abstract]
[Full Text]
-
Reinert, R. R.
(2004). Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother
53: 918-927
[Abstract]
[Full Text]
-
Pendland, S. L., Neuhauser, M. M., Prause, J. L.
(2002). In vitro bactericidal activity of ABT-773 and amoxicillin against erythromycin-susceptible and -resistant strains of Streptococcus pyogenes. J Antimicrob Chemother
49: 671-674
[Abstract]
[Full Text]
-
Neuhauser, M. M., Prause, J. L., Danziger, L. H., Pendland, S. L.
(2001). Postantibiotic Effects of ABT-773 and Amoxicillin-Clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob. Agents Chemother.
45: 3613-3615
[Abstract]
[Full Text]